Liquid Biopsy Tracks Herceptin Resistance in HER2+ Gastric Cancer Liquid Biopsy Tracks Herceptin Resistance in HER2+ Gastric Cancer
Circulating tumor DNA profiling can provide novel insights into gene alterations that underlie trastuzumab resistance in HER2+ metastatic gastric cancer.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Hematology | HER2 | Herceptin